← Oncology Approval Tracker

FDA DECISION ·

Pimjetmi

pimicotinib · EMD Serono

FDA approvalNew therapyTenosynovial giant cell tumor
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Pimicotinib for adults with symptomatic tenosynovial giant cell tumor when resection could worsen functional limitation or cause severe morbidity.

SUPPORTING DATA

Evidence behind the decision

Study
MANEUVER: double-blind, randomized, placebo-controlled international trial.
Key result
Week-25 response by blinded central review was 56% (95% CI 42-68) versus 3.2% (95% CI 0.1-17).
Safety to report
FDA warns about hepatotoxicity, embryo-fetal toxicity and increased creatinine without impaired renal function.
Evidence limits
The trial compared treatment with placebo, not another active TGCT therapy. FDA's annual novel-drug table lists November 13; the approval letter and oncology notice establish November 10 as the action date.

LAMPGEN ANALYSIS

Why it matters

This nonmalignant tumor decision fits the tracker's stated scope. Functional outcomes matter alongside radiographic response.

What research teams should watch

Document surgical risk, preserve consistent baseline imaging, and standardize joint-function and patient-reported assessments.

PRIMARY RECORDS

Sources